Food Allergy News and Research

DBV Submits Viaskin Peanut Treatment for FDA Biologics License

DBV Technologies today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age. Viaskin Peanut is the Company’s lead product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system

AAFA Joins Other Groups to Promote the Teal Pumpkin Project for a Safer Halloween

This Halloween across America, teal pumpkins will signal safe treats for trick-or-treaters with food allergies as part of the Teal Pumpkin Project, an awareness initiative jointly supported this year by Food Allergy Research & Education (FARE), the Asthma and Allergy Foundation of America and several other groups.

Soy and Milk Allergy Alerts - MyoWhey Chocolate Cookie Crunch

Purus Labs Issues Allergy Alert on Undeclared Milk and Soy in MyoWhey For Immediate Release September 20, 2018 Contact Consumers 214-221-1813 Announcement Purus Labs, Inc of Plano, Texas is recalling MyoWhey Chocolate Cookie Crunch,because it may contain undeclared milk and soy. This only effects products with Lot number PL: 0100518 Exp: 04/2020. People who have an allergy or severe sensitivity to milk and soy run the risk of serious or life-threatening allergic reaction if they consume...

AAFA Applauds Walgreens and Kaléo Partnership, Increasing Patient Access to Life-Saving Epinephrine

Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® available through Walgreens locations nationwide. The Asthma and Allergy Foundation of America (AAFA) applauds this effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.

Walgreens Locations Will Now Carry AUVI-Q Epinephrine Auto-Injectors

Walgreens and kaléo, a privately-held pharmaceutical company, are working together to improve access to epinephrine auto-injectors by making kaléo’s AUVI-Q® 0.15 mg and 0.3 mg available through Walgreens locations nationwide. This comes in an effort to help thousands of Americans with their epinephrine needs during the back to school season, as supply issues have been reported to the U.S. Food and Drug Administration (FDA) by other manufacturers.

Epinephrine Nasal Spray Gets Fast Track Status From FDA as a Possible Treatment for Life-Threatening Food Allergy Reactions

INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s epinephrine nasal spray as an investigational treatment for anaphylaxis, an acute, life-threatening allergic reaction requiring urgent treatment.

FDA Approves First Generic Competitor of EpiPen Epinephrine Auto-Injector

The U.S. Food and Drug Administration today approved the first generic version of EpiPen and EpiPen Jr (epinephrine) auto-injector for the emergency treatment of allergic reactions, including those that are life-threatening (anaphylaxis), in adults and pediatric patients who weigh more than 33 pounds. Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths.

Kaléo Confirms U.S. Availability of AUVI-Q® Auto-injector for Back-to-School Season

Kaléo, a privately-held pharmaceutical company, today commented on reports of continued manufacturing delays of epinephrine auto-injectors in the United States. Kaléo confirmed that AUVI-Q® (epinephrine injection, USP) Auto-injectors are available for prescription and are not affected by the manufacturing delays reported by other epinephrine auto-injector manufacturers. Kaléo has sufficient supply to meet any anticipated demand. For live assistance in filling an AUVI-Q prescription, any patient,

FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies

Genentech announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair® (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to them through FDA approval.

Updated Mylan Statement on U.S. Supply of EpiPen Auto-Injectors

[PRESS RELEASE] Our manufacturing partner Meridian Medical Technologies, a Pfizer company, continues to experience interruptions in the production of EpiPen® (epinephrine injection, USP) 0.3 mg and EpiPen Jr® (epinephrine injection, USP) 0.15 mg Auto-Injectors. Over the past few months, there has been intermittent supply of EpiPen at wholesalers and pharmacies. We are actively exploring several options with Pfizer that would help stabilize supply.

Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
8201 Corporate Drive Suite 1000 Landover, MD 20785
Phone: 1-800-7-ASTHMA (1.800.727.8462)
-->
×
×
×
×